RNS Number: 9591 I Futura Medical PLC 06 April 2020. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9565 I Futura Medical PLC 06 April 2020. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Futura Medical (FUT.L): Confirmation of FDA minutes Share price: 9.4p; Market Capitalisation: £23.0m Futura Medical, a developer of sexual health and pain therapies, received official minutes from the US FDA following its pre-submission meeting on 24 February 2020. The meeting minutes confirmed that the FDA agreed to a De Novo medical device application pathway for MED3000, a topical treatment for Erectile Dysfunction. The minutes indicate Futura must pursue a further pre-submission meeting to further discuss clinical sufficiency and/or post-marketing requirements. In December 2019, a Phase 3 trial testing MED2005, which contained GTN, an active pharmaceutical ingredient plus MED300, failed to show a statistically significant and clinically meaningful difference to the placebo control (MED300 only). As a result, Futura intended to progress regulatory approval for MED300 as a medical device. The outcome of the FDA meeting is a positive result for the commercialisation of MED300. The medical device is usually a shorter regulatory timeline than a therapy and Futura is targeting regulatory submissions to the US and EU regulators in the next six months. #FUM
RNS Number: 8130 I Futura Medical PLC 06 April 2020 6 April 2020. Futura Confirms Receipt of US FDA Minutes. Futura Medical plc, a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys ® technology and currently focused on sexual health and pain, is pleased to announce that it has received official...
Futura Medical Plc #FUM announced, in its audited results for the year ended 31 December 2019, that revenues stood at £31,778 compared to nil revenues in the previous year. Loss after tax widened to £8.9 million from £5.9 million.
Futura are awaiting the meeting minutes and expect to pursue regulatory approval for MED3000 as a medical device with a De Novo Classification in the USA.. UK partner Thornton& Ross received feedback from UK Medicines and Healthcare products Regulatory Agency in February 2019 requiring additional laboratory work to be conducted to support the UK...
RNS Number: 1732 G Futura Medical PLC 16 March 2020. Futura Medical plc, a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal technology DermaSys ® and currently focused on sexual health and pain, will announce its audited results for the year ended 31 December 2019 on Wednesday, 1 April 2020..
Futura Medical Plc (FUM.L) Announced plans to host an Investor Seminar in London for analysts and institutional investors on Thursday, 26 March 2020. The seminar follows an extensive internal evaluation of the clinical data from the Phase 3 study ("FM57") announced on 10 December 2019. Ken James, Executive Director and Head of R&D will present the Company's ongoing research and analysis of the FM57 and MED3000. #FUM
RNS Number: 0384 F Futura Medical PLC 05 March 2020. Futura Medical plc, a pharmaceutical company developing a portfolio of innovative products based on its on its proprietary, transdermal technology DermaSys ® and currently focused on sexual health and pain, announces plans to host an Investor Seminar in London for analysts and institutional investors on...
RNS Number: 3464 E Futura Medical PLC 27 February 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2385 D Futura Medical PLC 17 February 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Futura Medical Plc #FUM announced that it is pursuing the medical device regulatory pathway for its erectile dysfunction (ED) product, which utilised the DermaSys technology and was used as the control formulation in FM57 and is now known as MED3000. Separately, in its regulatory update the company announced that it was planning consultations with external regulators to provide clarity on potential timing and further requirements for approval in both the EU and USA.
RNS Number: 8373 C Futura Medical PLC 13 February 2020. Futura provides update on positive EU regulatory discussions and further ongoing analysis of FM57. On 20 December 2019, the Company announced that it was planning consultations with external regulators to provide clarity on potential timing and further requirements for approval in both the EU and USA.
RNS Number: 3467 B Futura Medical PLC 30 January 2020 30 January 2020. Futura Medical plc, a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 245,626,926 Ordinary...
Futura Medical plc, a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, announces the issue of 341,659 new ordinary shares of 0.2 pence each in respect of the 2019 remuneration of its Non-Executive Directors.. For 2019, these were issued at 6.01 pence per share, being the average closing mid-market price...
RNS Number: 4887 A Futura Medical PLC 21 January 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 4857 A Futura Medical PLC 21 January 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1981 A Futura Medical PLC 17 January 2020. Result of General Meeting, Issue of Equity, Admission and Total Voting Rights. Futura Medical plc, a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys ® drug delivery technology and focused on sexual health and pain, announces that, at its...
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    204.66M

Company Profile

Search WHO WE ARE Home About us Who we are Futura Medical is an innovative R&D company with a pipeline of products in late stage development. We are experts in transdermal delivery and have developed an advanced proprietary transdermal technology, DermaSys®.

Classification

Market Indices-

Locations

HQ
Surrey Technology Centre
40 Occam Road
Guildford
GU2 7YG
Watchlist